Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Shares of Gentium S.p.A. (NASDAQ:GENT) jumped $4.85 (50%) to $14.61 on Friday after EMA's CHMP backed approval of Defitelio defibrotide
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury